包装 | 价格(元) |
10mM (in 1mL DMSO) | 电议 |
5mg | 电议 |
10mg | 电议 |
Cell lines | HCT116, HT-29 |
Preparation Method | Ten millimolar Mitomycin C is prepared in 100% dimethyl sulfoxide, stored as small aliquots at -80℃ and then diluted as needed in cell culture medium. |
Reaction Conditions | 5 μM,12 or 24h |
Applications | Mitomycin C is a mitomycin that is used as a chemotherapeutic agent by virtue of its antitumour activity. Mitomycin C not only potentiates TRAIL-induced apoptosis in HCT116 (p53–/–) colon cancer cells but also sensitizes TRAIL- resistant colon cancer cells HT-29 to the cytokine. Mitomycin C inhibits HT-29 with IC50of 40 nM. |
Animal models | Nude mice (6 weeks) injected subcutaneously with 1 × 106 HCT116 (p53–/–) or 2 × 106HT-29 cells mixed with Matrigel |
Preparation Method | Ten millimolar Mitomycin C is prepared in 100% dimethyl sulfoxide, stored as small aliquots at -80℃ and then diluted as needed in cell culture medium. |
Dosage form | 1 mg/kg, Intraperitoneal injection |
Applications | Mitomycin C suppresses tumor growth significantly and does not impact the weight of the mice with TRAIL, indicating that the therapeutic combination of Mitomycin C and TRAIL is well-tolerated and has anti-tumor activity in vivo. |
文献引用 | |
产品描述 | Mitomycin C, a kind of antibiotic isolated from Streptomyces caespitosus or Streptomyces lavendulae, inhibits DNA synthesis through covalent mitomycin C-DNA adduct with EC50 values of 0.14μM in PC3 cells. Mitomycin C is an antibiotic that has demonstrated antitumor activity in preclinical and clinical studies and is widely used to treat various cancers. Mitomycin C is known to act synergistically with capecitabine and irinotecan. Some studies suggested that the combination of 5-FU plus Mitomycin C is more active in vitro than mono-therapy in colorectal cancer. The efficacy of the combination of Mitomycin C with other cytotoxic agents such as capecitabine and raltiterxed for colorectal cancer has been reported.[1] Mitomycin C not only potentiates TRAIL-induced apoptosis in HCT116 (p53–/–) colon cancer cells but also sensitizes TRAIL-resistant colon cancer cells HT-29 to the cytokine. At a mechanistic level, Mitomycin C downregulates cell survival proteins, including Bcl2, Mcl-1 and Bcl-XL, and upregulates pro-apoptotic proteins including Bax, Bim and the cell surface expression of TRAIL death receptors DR4 and DR5. Besides, the result of cell experiment indicates that Mitomycin C inhibits HT-29 with IC50of 40 nM. [1,2] Mitomycin C also plays an effective role in antitumor in vivo. For in vivo experiment, Mitomycin C suppressed tumor growth significantly and did not impact the weight of the mice with TRAIL, indicating that the therapeutic combination of Mitomycin C and TRAIL is well-tolerated and has anti-tumor activity in vivo. [1] References: |